CD70 and glioblastoma: The importance of determining an effective dose was also demonstrated by a study on TanCAR targeting CD70 and B7-H3, both of which are expressed in glioblastoma and have been studied individually, where there was incomplete eradication and, ultimately, antigen loss [199].